Amended Quarterly Report (10-q/a)
February 16 2017 - 6:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
|
|
|
|
FORM 10-Q/A
(Amendment No
. 1)
|
|
(Mark One)
☒
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2016
or
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
FOR THE TRANSITION PERIOD FROM
TO
Commission File Number: 001-36818
|
|
|
|
TRACON Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
Delaware
|
|
34-2037594
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
8910 University Center Lane, Suite 700,
San Diego CA
|
|
92122
|
(Address of principal executive offices)
|
|
(Zip Code)
|
858-550-0780
(Registrant’s telephone number, including area code)
___________________________________________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes
☒
No
☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes
☒
No
☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
|
|
☐
|
|
Accelerated filer
|
|
☐
|
Non-accelerated filer
|
|
☐
(Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
|
☒
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
☐
No
☒
The number of outstanding shares of the registrant’s common stock as of November 4, 2016 was 13,065,971.
EXPLANATORY NOTE
TRACON Pharmaceuticals, Inc. filed its Quarterly Report on Form 10-Q for the period ended September 30, 2016, on November 9, 2016 (the “Original Filing”). TRACON is filing this Amendment No. 1 on Form 10-Q/A to refile Exhibit 10.1 thereto. This Amendment No. 1 on Form 10-Q/A does not reflect subsequent events occurring after the filing date of the Original Filing or modify or update any disclosures made in the Original Filing, except as described above.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
TRACON Pharmaceuticals, Inc.
|
Date: February 15, 2017
|
By:
|
|
/s/ Charles P. Theuer, M.D., Ph.D.
|
|
|
|
Charles P. Theuer, M.D., Ph.D.
|
|
|
|
President and Chief Executive Officer
|
|
|
|
(principal executive officer)
|
|
|
|
Date: February 15, 2017
|
By:
|
|
/s/ Patricia L. Bitar, C.P.A.
|
|
|
|
Patricia L. Bitar, C.P.A.
|
|
|
|
Chief Financial Officer
|
|
|
|
(
principal financial and accounting officer
)
|
3
INDEX TO EXHIBITS TO FORM 10-Q/A
Exhibit
Number
|
|
Description of Document
|
10.1*
|
|
License and Option Agreement By and Between
Janssen Pharmaceutica N.V. and TRACON Pharmaceuticals, Inc., dated September 27, 2016.
|
31.1
|
|
Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.
|
31.2
|
|
Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.
|
|
*
|
Confidential treatment has been requested with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC.
|
4
TRACON Pharmaceuticals (NASDAQ:TCON)
Historical Stock Chart
From Mar 2024 to Apr 2024
TRACON Pharmaceuticals (NASDAQ:TCON)
Historical Stock Chart
From Apr 2023 to Apr 2024